Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about PAVmed Inc.
PAVmed Inc. News
PAVmed Inc. Quantitative Score
About PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
PAVmed Inc. Financials
Table Compare
Compare PAVM metrics with: | |||
|---|---|---|---|
Earnings & Growth | PAVM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PAVM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PAVM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PAVM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
PAVmed Inc. Income
PAVmed Inc. Balance Sheet
PAVmed Inc. Cash Flow
PAVmed Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
PAVmed Inc. Executives
| Name | Role |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman & Chief Executive Officer |
| Mr. Michael Adam Gordon | Executive Vice President, General Counsel & Secretary |
| Mr. Dennis M. McGrath CPA | President & Chief Financial Officer |
| Mr. Shaun M. O'Neill M.B.A. | Executive Vice President & Chief Operating Officer |
| Dr. Brian J. deGuzman M.D. | Executive Vice President, Chief Technology & Compliance Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Lishan Aklog M.D. | Chairman & Chief Executive Officer | 1966 | 953.2K | |
| Mr. Michael Adam Gordon | Executive Vice President, General Counsel & Secretary | Male | 1975 | 710.95K |
| Mr. Dennis M. McGrath CPA | President & Chief Financial Officer | Male | 1957 | 673.95K |
| Mr. Shaun M. O'Neill M.B.A. | Executive Vice President & Chief Operating Officer | Male | 1982 | 635.95K |
| Dr. Brian J. deGuzman M.D. | Executive Vice President, Chief Technology & Compliance Officer | 1965 | 427.6K |
PAVmed Inc. Insider Trades
| Date | 21 Feb |
| Name | Tasso Partners, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 21 Feb |
| Name | Tasso Partners, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 53974 |
| Date | 21 Oct |
| Name | Agrawal Sundeep |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 50000 |
| Date | 19 Sep |
| Name | Agrawal Sundeep |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 205000 |
| Date | 10 Sep |
| Name | Agrawal Sundeep |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 Feb | Tasso Partners, LLC | 10 percent owner | Disposed | 0 | |
| 21 Feb | Tasso Partners, LLC | 10 percent owner | Disposed | 53974 | |
| 21 Oct | Agrawal Sundeep | Director | Acquired | A-Award | 50000 |
| 19 Sep | Agrawal Sundeep | Director | Acquired | A-Award | 205000 |
| 10 Sep | Agrawal Sundeep | Director | Disposed | 0 |